How does the prognostic outlook for patients with double-hit lymphoma impact disease management? 

During the COLYM 2022 Annual Meeting, the Lymphoma Hub spoke with Narendranath Epperla, The Ohio State University, Columbus, US. We asked, How does the prognostic outlook for patients with double-hit lymphoma impact disease management?
Narendranath starts by defining double-hit lymphoma, explaining that patients with this classification are often refractory to the standard-of care front-line treatment R-CHOP. Narendranath then discusses outcome data for patients receiving dose-adjusted R-EPOCH, the typical front-line treatment for double- and triple-hit lymphoma.
Narendranath goes on to addresses the potential of more effective treatments than dose-adjusted R-EPOCH for these patients, reviewing studies that have evaluated the efficacy and toxicity of lenalidomide combined with R-CHOP, R-EPOCH, and dose-adjusted R-EPOCH. Promising results from early phase studies investigating other approaches, such as venetoclax combined with dose-adjusted R-EPOCH and CAR T-cell therapy, are also discussed.